Developer docs
API playgroundTry for free, no card

Search company profiles

Capricor Therapeutics

Full company profile

uuid000095g

Namestring
Capricor Therapeutics
Legal namestring
Capricor Therapeutics, Inc.
Websiteurl
capricor.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company developing cell and exosome-based therapeutics, with its lead asset Deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell (CDC) therapy in late-stage Phase 3 development for Duchenne muscular dystrophy (DMD). The company originated from Eduardo Marbán's research and was incorporated in 2005, gaining its public listing via a 2013 reverse merger with Nile Therapeutics. The HOPE-3 Phase 3 trial reported positive topline data in December 2025, meeting its primary upper-limb function endpoint (PUL v2.0, p=0.029) and demonstrating significant cardiac benefit (LVEF improvement versus placebo). The FDA is currently reviewing the BLA with a PDUFA target action date of August 22, 2026, following the lifting of a July 2025 Complete Response Letter. Deramiocel has received RMAT, Orphan Drug, and Rare Pediatric Disease designations. A second platform, StealthX, is a proprietary exosome-based delivery technology for oligonucleotides, proteins, and small molecules, currently in preclinical and early development.

The company is pre-revenue with no product sales as of Q1 2026 and reported a full-year 2025 net loss of $105M. Revenue to date has been limited to ratable recognition of upfront payments and government grants. Capitalization is supported by approximately $318M in cash as of December 31, 2025, a $150M December 2025 public offering, prior $75M (October 2024) and $23M (September 2023) raises, and a market capitalization of approximately $1.23B-$1.26B. Commercialization is structured around an exclusive partnership with Nippon Shinyaku (via its US subsidiary NS Pharma) covering the United States, Japan, and (as of September 2024) Europe, with up to $715M in potential milestones plus revenue sharing. The company is also building internal commercial capabilities and has filed a breach-of-contract lawsuit against NS Pharma/Nippon Shinyaku in May 2026 alleging inadequate launch preparation. The addressable DMD therapeutics market is projected to grow from $6.80B in 2025 to $26.88B by 2035, providing a substantial tailwind if Deramiocel secures approval.

Short descriptiontext

Capricor Therapeutics is a clinical-stage biotechnology company developing Deramiocel, an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy, alongside a proprietary StealthX exosome delivery platform, targeting rare disease patients globally through its Nippon Shinyaku partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy biotechnology, exosome therapeutics, duchenne muscular dystrophy, regenerative medicine, biologics manufacturing
Industry1 code
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology — Cell and Exosome Therapeutics for Rare Diseases
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Revenue (Projected)
TypeOne Time License
Description

Capricor is pre-revenue with no product sales. Upon FDA approval of Deramiocel, the company expects to generate product revenue from sales in the United States through its partnership with Nippon Shinyaku and potentially through direct sales capabilities.

biospace.com
2Milestone Payments from Nippon Shinyaku
TypeLicensing Royalties
Description

Capricor receives milestone payments tied to development, regulatory, and commercial achievements under its agreement with Nippon Shinyaku. Potential milestones up to $715 million, plus revenue sharing from product sales in licensed territories.

finance.yahoo.com
3Ratable Recognition of Upfront Payment
TypeSubscription Recurring
Description

Revenue recognized ratably from the $30 million upfront payment received from Nippon Shinyaku in Q1 2022 under the US Exclusive Commercialization and Distribution Agreement. Q3 2023 revenue was $6.2 million from this recognition.

capricor.com
4Government Grants
TypeProfessional Services
Description

Capricor has received funding from the California Institute for Regenerative Medicine (CIRM), classified as a loan/liability pending project completion outcomes.

capricor.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1StealthX™
Description

Proprietary exosome platform technology for delivering nucleic acids, proteins, and small molecules to treat or prevent a variety of diseases

capricor.com
Core offering1 text field

Capricor Therapeutics develops allogeneic cardiosphere-derived cell therapies, with its lead product candidate Deramiocel (CAP-1002) in Phase 3 development for Duchenne muscular dystrophy, and a proprietary StealthX™ exosome platform for delivering nucleic acids, proteins, and small molecules to treat or prevent various diseases. The company is pre-commercial with no approved products and no product revenue as of 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 54% slowing of skeletal muscle disease progression in DMD patients treated with Deramiocel versus placebo
+4 more records
Product overview1 text field

Capricor Therapeutics is a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases. The company's product portfolio consists of two core platforms: (1) Deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy in late-stage Phase 3 development for Duchenne muscular dystrophy, representing the lead commercial candidate; and (2) the StealthX™ exosome platform, a proprietary technology for engineering exosomes to deliver therapeutic cargo including oligonucleotides, proteins, and small molecules. These platforms address distinct therapeutic approaches - cell therapy for direct treatment of muscular and cardiac degeneration, and exosome-based delivery for broader applications in vaccinology and targeted therapeutics.

Product and service2 records
1Deramiocel (CAP-1002)
CategoryCell Therapy — Lead Product Candidate
Description

An allogeneic cardiosphere-derived cell therapy in Phase 3 HOPE-3 clinical development for Duchenne muscular dystrophy (DMD). Demonstrates immunomodulatory, antifibrotic, and regenerative effects for dystrophinopathies and heart disease. Has received FDA RMAT, Orphan Drug, and Rare Pediatric Disease designations. Developed and manufactured by Capricor for distribution via its exclusive partner Nippon Shinyaku/NS Pharma in the US and Japan.

2StealthX Exosome Platform
CategoryExosome-based Therapeutic Delivery Platform
Description

Proprietary exosome technology platform for developing next-generation therapeutics. Enables scalable production and loading of therapeutic oligonucleotides (siRNA, PMO), proteins, and small molecules into exosomes for targeted drug delivery. Used in preclinical development for vaccinology applications including an NIH-collaborated SARS-CoV-2 vaccine program.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Nippon Shinyaku Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Capricor signed a binding term sheet with Nippon Shinyaku to expand commercialization of Deramiocel for Duchenne muscular dystrophy in Europe. Capricor receives a $20 million upfront payment, a $15 million equity investment, and potential milestone payments up to $715 million. Capricor develops and manufactures the drug for approved regions while Nippon Shinyaku handles sales and distribution. This agreement builds upon the existing US and Japan distribution agreement.

capricor.com
2Nippon Shinyaku Co., Ltd. (NS Pharma US Subsidiary)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-17
Description

Exclusive commercialization and distribution agreement for Deramiocel (CAP-1002) for DMD in the United States and Japan. The agreement includes a $15 million equity investment, $20 million upfront payment, and potential milestones up to $715 million. Nippon Shinyaku's US subsidiary NS Pharma handles US commercialization, while Nippon Shinyaku handles Japan distribution.

globenewswire.com
3Nippon Shinyaku Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

European expansion of existing partnership for Deramiocel commercialization. The deal includes revenue sharing from product sales in European markets, extending Capricor's cash runway into 2026. Capricor will develop and manufacture the therapy while Nippon Shinyaku handles commercialization in Europe, subject to regulatory approval.

finance.yahoo.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2023-07-13
Description

Capricor partnered with Parent Project Muscular Dystrophy to host a webinar providing community updates on Phase 3 HOPE-3 trial results. PPMD is a patient advocacy organization that supports families and drives research for Duchenne muscular dystrophy.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-24
Description

Collaboration with NIH for clinical trial of novel exosome-based multivalent vaccine for SARS-CoV-2. Capricor's StealthX™ exosome platform technology is being utilized for this vaccine development program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pfizer is a large biopharma that has historically run DMD gene therapy programs (e.g., fordadistrogene movaparvovec). Comparable as a deep-pocketed incumbent competing in the same DMD space, but with a broader portfolio and AAV-based rather than cell-based modality.

2bluebird bio
TypeBroad incumbent
Description

bluebird is a commercial-stage gene and cell therapy company with approved products (Lyfgenia, Zynteglo, Skysona). Comparable as a rare-disease cell/gene therapy developer, though operating with lentiviral gene modification rather than cardiosphere-derived cells.

TypeDirect peer
Description

PTC commercializes Translarna (ataluren) for nonsense-mutation DMD and has an active DMD pipeline (including vatiquinone). Comparable to Capricor as a DMD-focused commercial/clinical-stage rare disease biotech, though with a small-molecule rather than cell therapy approach.

TypeDirect peer
Description

Solid Biosciences is a clinical-stage gene therapy company developing SGT-003 for DMD using an AAV-SLB101 capsid. Directly comparable to Capricor as a DMD-focused clinical-stage company, though pursuing gene therapy rather than cell therapy.

TypeDirect peer
Description

Regenxbio is developing RGX-202, an AAV gene therapy for DMD, leveraging its NAV technology platform. Directly comparable as a clinical-stage DMD gene therapy developer using a differentiated delivery platform.

6Athersys
TypeEmerging player
Description

Athersys (now operating as Helux) is a clinical-stage regenerative medicine company developing MultiStem, an off-the-shelf allogeneic cell therapy. Comparable as an early-stage allogeneic cell therapy developer, though with broader indications and a less advanced pipeline.

TypeEmerging player
Description

Helixmith (formerly ViroMed, formerly VM BioPharma) is a clinical-stage gene therapy company developing Engensis (donaperminotide pegol) for DMD and other indications. Comparable as a DMD-focused clinical-stage developer, though pursuing a plasmid DNA rather than cell therapy approach.

TypeDirect peer
Description

Mesoblast develops allogeneic cell therapies (remestemcel-L, rexlemestrocel-L) for inflammatory and cardiac conditions. Directly comparable as an allogeneic, off-the-shelf cell therapy developer using proprietary cell platforms — the closest pure cell-therapy analog to Deramiocel.

TypeBroad incumbent
Description

Vertex is a leader in cell and gene therapy following the Casgevy approval for sickle cell disease and beta-thalassemia, with a broad pipeline across CF and rare diseases. Comparable as a commercial-stage cell/gene therapy company, though not focused on DMD.

TypeDirect peer
Description

Sarepta is the leading commercial-stage DMD therapeutics company, with the approved gene therapy Elevidys and exon-skipping drugs (Exondys 51, Vyondys 53, Amondys 45). It is the most direct competitive comparable to Capricor given overlapping patient population, though it operates via gene therapy and antisense mechanisms rather than cell therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Capricor Therapeutics

Biotechnology — Cell and Exosome Therapeutics for Rare Diseasescapricor.com

Capricor Therapeutics is a clinical-stage biotechnology company developing Deramiocel, an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy, alongside a proprietary StealthX exosome delivery platform, targeting rare disease patients globally through its Nippon Shinyaku partnership.

What Capricor Therapeutics does

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company developing cell and exosome-based therapeutics, with its lead asset Deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell (CDC) therapy in late-stage Phase 3 development for Duchenne muscular dystrophy (DMD). The company originated from Eduardo Marbán's research and was incorporated in 2005, gaining its public listing via a 2013 reverse merger with Nile Therapeutics. The HOPE-3 Phase 3 trial reported positive topline data in December 2025, meeting its primary upper-limb function endpoint (PUL v2.0, p=0.029) and demonstrating significant cardiac benefit (LVEF improvement versus placebo). The FDA is currently reviewing the BLA with a PDUFA target action date of August 22, 2026, following the lifting of a July 2025 Complete Response Letter. Deramiocel has received RMAT, Orphan Drug, and Rare Pediatric Disease designations. A second platform, StealthX, is a proprietary exosome-based delivery technology for oligonucleotides, proteins, and small molecules, currently in preclinical and early development.

The company is pre-revenue with no product sales as of Q1 2026 and reported a full-year 2025 net loss of $105M. Revenue to date has been limited to ratable recognition of upfront payments and government grants. Capitalization is supported by approximately $318M in cash as of December 31, 2025, a $150M December 2025 public offering, prior $75M (October 2024) and $23M (September 2023) raises, and a market capitalization of approximately $1.23B-$1.26B. Commercialization is structured around an exclusive partnership with Nippon Shinyaku (via its US subsidiary NS Pharma) covering the United States, Japan, and (as of September 2024) Europe, with up to $715M in potential milestones plus revenue sharing. The company is also building internal commercial capabilities and has filed a breach-of-contract lawsuit against NS Pharma/Nippon Shinyaku in May 2026 alleging inadequate launch preparation. The addressable DMD therapeutics market is projected to grow from $6.80B in 2025 to $26.88B by 2035, providing a substantial tailwind if Deramiocel secures approval.

Capricor Therapeutics firmographics

Firmographics
Name
Capricor Therapeutics
Legal name
Capricor Therapeutics, Inc.
Website
https://capricor.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Capricor Therapeutics is a clinical-stage biotechnology company developing Deramiocel, an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy, alongside a proprietary StealthX exosome delivery platform, targeting rare disease patients globally through its Nippon Shinyaku partnership.
Ownership category
akta.pro rank

Capricor Therapeutics industry classification

Industry
Product category
Biotechnology — Cell and Exosome Therapeutics for Rare Diseases
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy biotechnology
  • Exosome therapeutics
  • Duchenne muscular dystrophy
  • Regenerative medicine
  • Biologics manufacturing

Where Capricor Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Capricor Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Revenue (Projected): Capricor is pre-revenue with no product sales. Upon FDA approval of Deramiocel, the company expects to generate product revenue from sales in the United States through its partnership with Nippon Shinyaku and potentially through direct sales capabilities.
  2. Milestone Payments from Nippon Shinyaku: Capricor receives milestone payments tied to development, regulatory, and commercial achievements under its agreement with Nippon Shinyaku. Potential milestones up to $715 million, plus revenue sharing from product sales in licensed territories.
  3. Ratable Recognition of Upfront Payment: Revenue recognized ratably from the $30 million upfront payment received from Nippon Shinyaku in Q1 2022 under the US Exclusive Commercialization and Distribution Agreement. Q3 2023 revenue was $6.2 million from this recognition.
  4. Government Grants: Capricor has received funding from the California Institute for Regenerative Medicine (CIRM), classified as a loan/liability pending project completion outcomes.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Capricor Therapeutics product offering

Product offering

Core offering

Capricor Therapeutics develops allogeneic cardiosphere-derived cell therapies, with its lead product candidate Deramiocel (CAP-1002) in Phase 3 development for Duchenne muscular dystrophy, and a proprietary StealthX™ exosome platform for delivering nucleic acids, proteins, and small molecules to treat or prevent various diseases. The company is pre-commercial with no approved products and no product revenue as of 2026.

Product overview

Capricor Therapeutics is a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases. The company's product portfolio consists of two core platforms: (1) Deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy in late-stage Phase 3 development for Duchenne muscular dystrophy, representing the lead commercial candidate; and (2) the StealthX™ exosome platform, a proprietary technology for engineering exosomes to deliver therapeutic cargo including oligonucleotides, proteins, and small molecules. These platforms address distinct therapeutic approaches - cell therapy for direct treatment of muscular and cardiac degeneration, and exosome-based delivery for broader applications in vaccinology and targeted therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • StealthX™: Proprietary exosome platform technology for delivering nucleic acids, proteins, and small molecules to treat or prevent a variety of diseases

Products and services

  • Deramiocel (CAP-1002) An allogeneic cardiosphere-derived cell therapy in Phase 3 HOPE-3 clinical development for Duchenne muscular dystrophy (DMD). Demonstrates immunomodulatory, antifibrotic, and regenerative effects for dystrophinopathies and heart disease. Has received FDA RMAT, Orphan Drug, and Rare Pediatric Disease designations. Developed and manufactured by Capricor for distribution via its exclusive partner Nippon Shinyaku/NS Pharma in the US and Japan.
  • StealthX Exosome Platform Proprietary exosome technology platform for developing next-generation therapeutics. Enables scalable production and loading of therapeutic oligonucleotides (siRNA, PMO), proteins, and small molecules into exosomes for targeted drug delivery. Used in preclinical development for vaccinology applications including an NIH-collaborated SARS-CoV-2 vaccine program.

Quantifiable outcome

  • 54% slowing of skeletal muscle disease progression in DMD patients treated with Deramiocel versus placebo
  • +4 more outcomes

Companies that use Capricor Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Capricor Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Capricor Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Nippon Shinyaku Co., Ltd.coreStrategic or Co-development Partner · 17 September 2024Capricor signed a binding term sheet with Nippon Shinyaku to expand commercialization of Deramiocel for Duchenne muscular dystrophy in Europe. Capricor receives a $20 million upfront payment, a $15 million equity investment, and potential milestone payments up to $715 million. Capricor develops and manufactures the drug for approved regions while Nippon Shinyaku handles sales and distribution. This agreement builds upon the existing US and Japan distribution agreement.
  • Nippon Shinyaku Co., Ltd. (NS Pharma US Subsidiary)coreChannel Partner/ Reseller/ Distributor · 17 September 2024Exclusive commercialization and distribution agreement for Deramiocel (CAP-1002) for DMD in the United States and Japan. The agreement includes a $15 million equity investment, $20 million upfront payment, and potential milestones up to $715 million. Nippon Shinyaku's US subsidiary NS Pharma handles US commercialization, while Nippon Shinyaku handles Japan distribution.
  • Nippon Shinyaku Co., Ltd.coreStrategic or Co-development Partner · 17 September 2024European expansion of existing partnership for Deramiocel commercialization. The deal includes revenue sharing from product sales in European markets, extending Capricor's cash runway into 2026. Capricor will develop and manufacture the therapy while Nippon Shinyaku handles commercialization in Europe, subject to regulatory approval.
  • Parent Project Muscular Dystrophy (PPMD)minorGTM or Marketing Partner · 13 July 2023Capricor partnered with Parent Project Muscular Dystrophy to host a webinar providing community updates on Phase 3 HOPE-3 trial results. PPMD is a patient advocacy organization that supports families and drives research for Duchenne muscular dystrophy.
  • National Institutes of Health (NIH)minorStrategic or Co-development Partner · 24 January 2023Collaboration with NIH for clinical trial of novel exosome-based multivalent vaccine for SARS-CoV-2. Capricor's StealthX™ exosome platform technology is being utilized for this vaccine development program.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Capricor Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Pfizer is a large biopharma that has historically run DMD gene therapy programs (e.g., fordadistrogene movaparvovec). Comparable as a deep-pocketed incumbent competing in the same DMD space, but with a broader portfolio and AAV-based rather than cell-based modality.
  • bluebird bio: bluebird is a commercial-stage gene and cell therapy company with approved products (Lyfgenia, Zynteglo, Skysona). Comparable as a rare-disease cell/gene therapy developer, though operating with lentiviral gene modification rather than cardiosphere-derived cells.
  • Vertex Pharmaceuticals: Vertex is a leader in cell and gene therapy following the Casgevy approval for sickle cell disease and beta-thalassemia, with a broad pipeline across CF and rare diseases. Comparable as a commercial-stage cell/gene therapy company, though not focused on DMD.

Direct peers

  • PTC Therapeutics: PTC commercializes Translarna (ataluren) for nonsense-mutation DMD and has an active DMD pipeline (including vatiquinone). Comparable to Capricor as a DMD-focused commercial/clinical-stage rare disease biotech, though with a small-molecule rather than cell therapy approach.
  • Solid Biosciences: Solid Biosciences is a clinical-stage gene therapy company developing SGT-003 for DMD using an AAV-SLB101 capsid. Directly comparable to Capricor as a DMD-focused clinical-stage company, though pursuing gene therapy rather than cell therapy.
  • Regenxbio: Regenxbio is developing RGX-202, an AAV gene therapy for DMD, leveraging its NAV technology platform. Directly comparable as a clinical-stage DMD gene therapy developer using a differentiated delivery platform.
  • Mesoblast: Mesoblast develops allogeneic cell therapies (remestemcel-L, rexlemestrocel-L) for inflammatory and cardiac conditions. Directly comparable as an allogeneic, off-the-shelf cell therapy developer using proprietary cell platforms — the closest pure cell-therapy analog to Deramiocel.
  • Sarepta Therapeutics: Sarepta is the leading commercial-stage DMD therapeutics company, with the approved gene therapy Elevidys and exon-skipping drugs (Exondys 51, Vyondys 53, Amondys 45). It is the most direct competitive comparable to Capricor given overlapping patient population, though it operates via gene therapy and antisense mechanisms rather than cell therapy.

Emerging players

  • Athersys: Athersys (now operating as Helux) is a clinical-stage regenerative medicine company developing MultiStem, an off-the-shelf allogeneic cell therapy. Comparable as an early-stage allogeneic cell therapy developer, though with broader indications and a less advanced pipeline.
  • Helixmith: Helixmith (formerly ViroMed, formerly VM BioPharma) is a clinical-stage gene therapy company developing Engensis (donaperminotide pegol) for DMD and other indications. Comparable as a DMD-focused clinical-stage developer, though pursuing a plasmid DNA rather than cell therapy approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Capricor Therapeutics social profiles

Digital presence

Capricor Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Capricor Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Capricor Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Capricor Therapeutics funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Capricor Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capricor Therapeutics

What does Capricor Therapeutics do?

Capricor Therapeutics develops allogeneic cardiosphere-derived cell therapies, with its lead product candidate Deramiocel (CAP-1002) in Phase 3 development for Duchenne muscular dystrophy, and a proprietary StealthX™ exosome platform for delivering nucleic acids, proteins, and small molecules to treat or prevent various diseases. The company is pre-commercial with no approved products and no product revenue as of 2026.

Is Capricor Therapeutics a public or private company?

Capricor Therapeutics is a public company. It is classified as public and is currently operating.

When was Capricor Therapeutics founded?

Capricor Therapeutics was founded in 2005. It employs 51 to 100 people.

Where is Capricor Therapeutics based?

Capricor Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Capricor Therapeutics make money?

Four revenue lines are on record. Product Revenue (Projected) is the primary driver. The others are milestone Payments from Nippon Shinyaku, ratable Recognition of Upfront Payment and government Grants.

Who are Capricor Therapeutics's main competitors?

Broad incumbents on record are Pfizer, bluebird bio and Vertex Pharmaceuticals. Direct peers are PTC Therapeutics, Solid Biosciences, Regenxbio, Mesoblast and Sarepta Therapeutics. Emerging players are Athersys and Helixmith.

Does Capricor Therapeutics have an API?

No public API is recorded for Capricor Therapeutics.

What industry is Capricor Therapeutics in?

Capricor Therapeutics's product category is Biotechnology — Cell and Exosome Therapeutics for Rare Diseases. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialCAPR Stock Has Retail's Attention After SLS Rally - Here Are 2 Drugs With Better FDA Approval Odds This MonthCapricor's Deramiocel faces an FDA target date on Sunday after narrowing its application to Duchenne patients over nine. SLS shares jumped 156% after its leukemia vaccine trial showed median survival of 24 months. BiopharmaWatch estimates Savara's Molgramostim at 85% and Sanofi's Venglustat at 79% approval odds this month.StocktwitsCAPR Stock Has Retail’s Attention After SLS Rally — Here Are 2 Drugs With Better FDA Approval Odds This MonthCapricor Therapeutics (CAPR) faces an FDA target date Sunday for its Duchenne muscular dystrophy therapy Deramiocel, after narrowing its application. SLS shares jumped 156% after its leukemia vaccine trial showed median survival of 24 months. BiopharmaWatch estimates approval odds of 62% for CAPR, 85% for Savara, and 79% for Sanofi.TradingViewCAPR Stock Has Retail’s Attention After SLS Rally — Here Are 2 Drugs With Better FDA Approval Odds This MonthCapricor's Deramiocel faces an FDA target date on Sunday after narrowing its application to Duchenne patients over nine. SLS shares jumped 156% after its leukemia vaccine trial showed median survival of 24 months. BiopharmaWatch estimates Savara's Molgramostim at 85% approval odds, 23 points above Capricor's 62%.BenzingaCapricor Stock Rises: What's Going On? - Capricor Therapeutics (NASDAQ:CAPR)Capricor Therapeutics shares rose 2.29% to $8.49 on Tuesday ahead of the FDA's pending decision on its Duchenne muscular dystrophy therapy deramiocel. The FDA's PDUFA target date is Nov. 22, 2026, and the company's HOPE-3 Phase 3 data showed improved upper-limb function but a non-significant cardiac endpoint. The data could strengthen the drug's FDA case, though risks remain.PRESSBEETang Capital Reports Zero Capricor Stake After Stock Plunges 13% ...Middle EastTang Capital reported zero beneficial ownership of Capricor Therapeutics shares as of September 30, following a 13% stock drop. The disclosure follows a prior filing showing 7.1% ownership, and the FDA's November 22 action date for Deramiocel remains pending.StocktwitsSMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA TestSummit Therapeutics shares fell 20% after the FDA rejected its Ivonescimab-plus-chemotherapy application for lung cancer, citing lack of statistically significant survival benefit. Capricor Therapeutics faces a Nov.22 FDA decision on Deramiocel for Duchenne patients, after a prior advisory vote against its heart-disease evidence.TradingViewSMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA TestSummit Therapeutics shares fell 20% overnight after the FDA rejected its Ivonescimab combination for lung cancer, citing lack of statistically significant survival benefit. Capricor Therapeutics awaits a Nov.22 FDA decision on Deramiocel for Duchenne patients, having previously faced a negative advisory vote.Defense WorldCapricor Therapeutics (NASDAQ:CAPR) Earns Neutral Rating from Roth CapitalRoth Capital reaffirmed a neutral rating on Capricor Therapeutics, raising its price target to $10.50 from $7.00. The stock fell 6.9% to $9.53, while the consensus rating is Hold with a $30.09 target. Analysts forecast a -2.38 EPS for the current year.Business & FinancialSMMT Stock Plunges Overnight On FDA Rejection - CAPR Holders Feel The Jitters Ahead Of Their Own FDA TestSummit Therapeutics shares fell 20% overnight after the FDA rejected its Ivonescimab plus chemotherapy for advanced lung cancer, citing lack of statistically significant survival benefit. Capricor Therapeutics faces a Nov.22 FDA decision on Deramiocel for Duchenne patients, after a prior advisory panel vote against its heart-disease evidence.